These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 30204247)

  • 1. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
    DuBois SG; Laetsch TW; Federman N; Turpin BK; Albert CM; Nagasubramanian R; Anderson ME; Davis JL; Qamoos HE; Reynolds ME; Cruickshank S; Cox MC; Hawkins DS; Mascarenhas L; Pappo AS
    Cancer; 2018 Nov; 124(21):4241-4247. PubMed ID: 30204247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.
    Kummar S; Shen L; Hong DS; McDermott R; Keedy VL; Casanova M; Demetri GD; Dowlati A; Melcón SG; Lassen UN; Leyvraz S; Liu T; Moreno V; Patel J; Patil T; Mallick AB; Sousa N; Tahara M; Ziegler DS; Norenberg R; Arvis P; Brega N; Drilon A; Tan DSW
    Cancer; 2023 Dec; 129(23):3772-3782. PubMed ID: 37769113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.
    Bielack SS; Cox MC; Nathrath M; Apel K; Blattmann C; Holl T; Jenewein R; Klenk U; Klothaki P; Müller-Abt P; Ortega-Lawerenz S; Reynolds M; Scheer M; Simon-Klingenstein K; Stegmaier S; Tupper R; Vokuhl C; von Kalle T
    Ann Oncol; 2019 Nov; 30 Suppl 8():viii31-viii35. PubMed ID: 32223937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Larotrectinib followed by selitrectinib in a novel
    Goh XN; Seng MS; Loh AHP; Gupta A; Chang KTE; Iyer P
    J Oncol Pharm Pract; 2021 Mar; 27(2):485-489. PubMed ID: 32693686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
    Yang JCH; Brose MS; Castro G; Kim ES; Lassen UN; Leyvraz S; Pappo A; López-Ríos F; Reeves JA; Fellous M; Penault-Llorca F; Rudzinski ER; Tabatabai G; Vassal G; Drilon A; Trent J
    BMC Cancer; 2022 Jun; 22(1):625. PubMed ID: 35672677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib.
    Caldwell KJ; De La Cuesta E; Morin C; Pappo A; Helmig S
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28330. PubMed ID: 32452122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.
    Bielack SS; Cox MC; Nathrath M; Apel K; Blattmann C; Holl T; Jenewein R; Klenk U; Klothaki P; Müller-Abt P; Ortega-Lawerenz S; Reynolds M; Scheer M; Simon-Klingenstein K; Stegmaier S; Tupper R; Vokuhl C; von Kalle T
    Ann Oncol; 2019 Nov; 30(Suppl_8):viii31-viii35. PubMed ID: 31738425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
    Drilon A; Laetsch TW; Kummar S; DuBois SG; Lassen UN; Demetri GD; Nathenson M; Doebele RC; Farago AF; Pappo AS; Turpin B; Dowlati A; Brose MS; Mascarenhas L; Federman N; Berlin J; El-Deiry WS; Baik C; Deeken J; Boni V; Nagasubramanian R; Taylor M; Rudzinski ER; Meric-Bernstam F; Sohal DPS; Ma PC; Raez LE; Hechtman JF; Benayed R; Ladanyi M; Tuch BB; Ebata K; Cruickshank S; Ku NC; Cox MC; Hawkins DS; Hong DS; Hyman DM
    N Engl J Med; 2018 Feb; 378(8):731-739. PubMed ID: 29466156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A Case of Pediatric Soft Tissue Sarcoma with LMNA-NTRK1 Gene Fusion Treated with Larotrectinib under Single Patient Expanded Access System].
    Kato S; Fujimura J; Nozaki Y; Yamaguchi S; Takagi T; Hayashi T; Saito T; Henry D; Ku N; Suehara Y
    Gan To Kagaku Ryoho; 2019 Oct; 46(10):1595-1597. PubMed ID: 31631147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
    Hong DS; DuBois SG; Kummar S; Farago AF; Albert CM; Rohrberg KS; van Tilburg CM; Nagasubramanian R; Berlin JD; Federman N; Mascarenhas L; Geoerger B; Dowlati A; Pappo AS; Bielack S; Doz F; McDermott R; Patel JD; Schilder RJ; Tahara M; Pfister SM; Witt O; Ladanyi M; Rudzinski ER; Nanda S; Childs BH; Laetsch TW; Hyman DM; Drilon A
    Lancet Oncol; 2020 Apr; 21(4):531-540. PubMed ID: 32105622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report.
    Kubota Y; Kawano M; Iwasaki T; Itonaga I; Tsumura H; Kaku N; Tanaka K
    Medicine (Baltimore); 2023 Dec; 102(49):e36232. PubMed ID: 38065851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic strategies and clinical evolution of patients with infantile fibrosarcoma: a unique paediatric case series.
    Corral Sánchez MD; Jiménez Carrascoso R; Rubio Aparicio P; Plaza López de Sabando D; Sastre Urgelles A; Pozo-Kreilinger JJ; López Gutiérrez JC; Gómez Cervantes M; Ortiz Cruz EJ; Pérez-Martínez A
    Clin Transl Oncol; 2023 Nov; 25(11):3307-3311. PubMed ID: 37097530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors.
    Kim EE; Park CK; Kim SK; Phi JH; Paek SH; Choi JY; Kang HJ; Lee JH; Won JK; Yun H; Park SH
    Acta Neuropathol Commun; 2024 Jul; 12(1):118. PubMed ID: 39014476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib.
    Kummar S; Berlin J; Mascarenhas L; van Tilburg CM; Geoerger B; Lassen UN; Schilder RJ; Turpin B; Nanda S; Keating K; Childs BH; Chirila C; Laetsch TW; Hyman DM; Drilon A; Hong DS
    Curr Probl Cancer; 2021 Dec; 45(6):100734. PubMed ID: 33865615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study).
    Orbach D; Carton M; Khadir SK; Feuilly M; Kurtinecz M; Phil D; Vokuhl C; Koscielniak E; Pierron G; Lemelle L; Sparber-Sauer M
    ESMO Open; 2024 May; 9(5):103006. PubMed ID: 38657345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy.
    Lin R; Mallick AB; Wang ZX; Brown SA; Lu B; Jiang W
    Diagn Pathol; 2023 Oct; 18(1):116. PubMed ID: 37865792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tropomyosin receptor kinase inhibitors in the management of sarcomas.
    Wilding CP; Loong HH; Huang PH; Jones RL
    Curr Opin Oncol; 2020 Jul; 32(4):307-313. PubMed ID: 32541318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.
    Doebele RC; Davis LE; Vaishnavi A; Le AT; Estrada-Bernal A; Keysar S; Jimeno A; Varella-Garcia M; Aisner DL; Li Y; Stephens PJ; Morosini D; Tuch BB; Fernandes M; Nanda N; Low JA
    Cancer Discov; 2015 Oct; 5(10):1049-57. PubMed ID: 26216294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.
    Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
    Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.